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ARTICLE

Acute Myeloid Leukemia
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cross-sectional studies and correlation with
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ABSTRACT

O

besity correlates with hematologic malignancies including
leukemias, but risk of specific leukemia subtypes like acute
promyelocytic leukemia and underlying molecular mechanisms are
poorly understood. We explored multiple datasets for correlation between
leukemia, body mass index (BMI) and molecular features. In a populationbased study (n=5.2 million), we correlated BMI with promyelocytic
leukemia, and other acute myeloid, lymphoid or other leukemias. In crosssectional studies, we tested BMI deviation in promyelocytic leukemia trial
cohorts from that expected based on national surveys. We explored The
Cancer Genome Atlas for transcriptional signatures and mutations enriched
in promyelocytic leukemia and/or obesity, and confirmed a correlation
between body mass and FLT3 mutations in promyelocytic leukemia
cohorts by logistic regression. In the population-based study, hazard ratio
per 5 kg/m2 increase was: promyelocytic leukemia 1.44 (95%CI: 1.0-2.08),
non-promyelocytic acute myeloid leukemias 1.17 (95%CI: 1.10-1.26), lymphoid leukemias 1.04 (95%CI: 1.0-1.09), other 1.10 (95%CI: 1.04-1.15). In
cross-sectional studies, body mass deviated significantly from that expected
(Italy: P<0.001; Spain: P=0.011; USA: P<0.001). Promyelocytic leukemia
showed upregulation of polyunsaturated fatty acid metabolism genes.
Odds of FLT3 mutations were higher in obese acute myeloid leukemias
(odds ratio=2.4, P=0.007), whether promyelocytic or not, a correlation confirmed in the pooled promyelocytic leukemia cohorts (OR=1.22, 1.05-1.43
per 5 kg/m2). These results strengthen the evidence for obesity as a bona fide
risk factor for myeloid leukemias, and in particular APL. FLT3 mutations
and polyunsaturated fatty acid metabolism may play a previously underappreciated role in obesity-associated leukemogenesis.

Introduction
The etiology of acute myeloid leukemia (AML) remains poorly understood.
Genetic predisposition or clear exposure to environmental mutagenic agents
(smoking, benzene, radiation, prior chemotherapy) can be demonstrated only in a
minority of cases.1 Age is an independent risk factor, probably linked to the prohaematologica | 2020; 105(6)
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gressive mutation accumulation and clonal stem cell
expansion that accompanies aging.2 Although obesity has
recently emerged as a prominent risk factor for a variety of
solid tumors,3 its impact on hematologic neoplasms has
received less attention. A moderate but consistently positive correlation between body mass index (BMI) and incidence of leukemias has been identified in observational
studies,4-6 yet none of the collected evidence has been considered sufficiently strong to consider obesity as a bona fide
risk factor for AML.3,7 Most studies did not distinguish
between myeloid/lymphoid and acute/chronic forms, nor
between genetic subtypes within each form. AML is recognized as a highly heterogeneous disease with genetically diverse subtypes.8 Subtypes have radically different outcomes and, similarly, their risk may be differentially
affected by environmental factors. Identification of subtype-specific risk associations, however, is made difficult
by their rarity.
A genetic subset of AML, acute promyelocytic leukemia
(APL), is characterized by a specific chromosomal translocation (t15;17), homogeneous biology and response to
clinical agents all-trans retinoic acid (ATRA) and arsenic
trioxide, which have made it the most curable form of
AML to date.9 We previously demonstrated that the risk of
relapse after ATRA/idarubicin is significantly increased in
overweight/obese APL patients.10 In the present report, we
investigated the association of overweight/obesity with
the risk of developing APL and other leukemias. We
describe the results of multiple studies across four western
populations with significantly different dietary regimens
and prevalence of obesity. All the studies demonstrated
increased risk of developing APL in overweight/obesity
subjects. In an effort to generate mechanistic hypotheses
to explain this relationship, we analyzed transcriptomic
and mutational data from the AML project in The Cancer
Genome Atlas (TCGA)11 and identified alterations selectively associated with obesity and/or APL which may be
involved in obesity-associated leukemogenesis.

Methods
UK population-based study: data collection
and statistical methods
Full details of the methods for the UK population study were
described previously.6 The study was approved by the London
School of Hygiene and Tropical Medicine Ethics Committee. To
identify outcomes of specific leukemia sub-types, Clinical Practice
Research Datalink (CPRD) clinical records were searched for codes
relating to specific leukemia subgroups. We controlled for multiple
co-variates at time of the BMI record(s): age, smoking status, alcohol use, previous diabetes diagnosis, index of multiple deprivation, calendar period, and stratified by gender. We excluded people with missing smoking [49,206 of 5.24 million (0.9%)] and alcohol [394,196 of 5.24 million (7.5%)] status. Confidence intervals
(CI) in Figure 1 are presented at the 99% level; all other CIs are
presented at the 95% level.

Cross-sectional studies: data collection and statistical
methods
Acute promyelocytic leukemia cases from Spain were extracted
from the PETHEMA database to include 414 cases diagnosed
between 1998 and 2012. APL cases from Italy, where 134 adult
patients were treated under the AIDA protocol, were included in
the previously described cohort.10 APL cases from the USA includ1560

ed the entire cohort of the published AML The Cancer Genome
Atlas (TCGA) project11 (n=20) plus 22 additional APL cases, unselected for any clinical variable, diagnosed at Washington
University, St. Louis, MO, USA (Expanded TCGA cohort). For all
case cohorts, BMI was measured at the time of diagnosis.
Data collection was approved by the Research Ethics Board of
each participating institution, as referenced.11-14 Data sources for
expected BMI in the local population are described in the Online
Supplementary Appendix.
We compared the distribution of BMI observed in the three APL
case cohorts to the distribution of BMI expected in the general population of the same countries. Specifically, to calculate the expected
distribution of BMI in Italy, we used data from the Italian National
Institute of Statistics,14 and we selected the area of Lazio, where the
APL cases were diagnosed, in the years 2000-2010. For Spain, we
used data from the Eurostat,15 and we selected the general population of Spain in the year 2008, the only year available. For both
Italy and Spain, the expected BMI distribution was calculated using
the available age- and gender-specific BMI distribution of the general population classified into three categories (<25, 25-29.9, ≥30).
For the USA, we used the 2009-2010 data from the American
National Health and Nutrition Examination Survey.16 The expected
BMI distribution was calculated using the available race-, age-, and
gender-specific BMI distribution of the general population classified into four categories (<25, 25-29.9, 30.0-34.9, ≥35).
The global null hypothesis that the observed counts did not differ from the expected ones across the BMI categories was tested
in a null Poisson regression model, where the observed counts
were considered as dependent variable and the expected counts as
the offset. BMI was included in the model as an ordinal variable
to test the log-linear relationship between BMI and the observed
to expected ratio (i.e. to test for linear trend). Pearson's χ2 goodness
of fit test P-value was reported.

Expression data analysis
Expression data (RPKM matrix) were down-loaded from the
AML TCGA data portal. Cases with available RNAseq, BMI and
French-American-British (FAB) classification data (177 of 200)
were used in the present study. Cases were classified by FAB in
"APL" (FAB="M3") and "non-APL" (FAB ≠ "M3"), and by BMI in
"obese" (BMI ≥ 30) and "non-obese" (BMI < 30). Genes with < 0.2
reads per kilo base per million mapped reads (RPKM) in at least
75% of patients were removed.11 The Quantitative Set Analysis
for Gene Expression method, as implemented in the quSAGE
package15 in the R programming language (v3.2.3), was used to
conduct supervised gene set enrichment analysis. For each
expressed gene, the quSAGE algorithm calculates a probability
density function (PDF) of differential expression between two
groups of samples. For each gene set, it then calculates "activity",
i.e. the mean difference in log-expression of individual genes
included in a gene set. Gene sets with False Discovery Rate (FDR)
< 0.05 were considered significant. We focused on the Kyoto
Encyclopedia of Genes and Genomes (KEGG) and chemical and
genetic perturbations (CGP) gene set collections, down-loaded
from MSigDB (http://software.broadinstitute.org/gsea/msigdb/).
The CGP collection was used to confirm enrichment of previously
identified APL-specific gene signatures16 (Online Supplementary
Table S1). We focused on the KEGG collection, as it is enriched for
metabolism-associated gene annotations.16 The script to generate
the present results is available on request.

Mutational data analysis
For the analysis of the TCGA data, mutational data were
retrieved from the TCGA AML paper,11 and AML driver genes
(restricted to those with at least 2 mutations in the dataset) were
haematologica | 2020; 105(6)
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down-loaded from IntOgen.17 For each gene, different mutations
were conflated so that gene status in each patient was either
"mutated" or "wild-type". For each gene, we then calculated the
number of mutated or wild-type patients in the obese or nonobese groups, and calculated odds ratios (OR), 95% confidence
intervals (CI), and P-values by Fisher's test with BenjaminiHochberg correction. Only genes with >1 mutation in the dataset
were considered, using the fdsm package in R.
For the analysis of the retrospective cohort, FLT3 Internal
Tandem Duplication (ITD) mutational data were provided by the
referring centers. Logistic regression was used to calculate OR
with 95%CI.
Further details of the methods used are provided in the Online
Supplementary Appendix.

sis. These events were further classified in the following
groups: “APL” (n=26), “non APL-AML” (n=1,012), lymphoid leukemias (“LL”; n=2,823), and “other” (n=1,972).
Median time lapse between BMI measurement and diagnosis was similar across subgroups (APL: 1,810 days;
AML: 2,280 days; LL: 1,928 days; other: 1,894 days).
We fit BMI as a three-knot cubic spline and as a linear
term. There was no evidence of non-linearity (P=0.94),
suggesting that the relationship was best described by the
linear model. After adjusting for co-variates, per each 5
kg/m2 increase we obtained hazard ratios (HR) of 1.44 for

Table 1. Hazard ratios from the UK population study.

Disease

Results
Population-based cohort study in the UK
Overall characteristics of the 5.24 million UK adults
included in this study have been described previously.6 A
total of 5,833 subjects with a diagnosis of “leukemia” over
the observational time were included in the present analy-

APL
AML
LL
Other

N. of
events

Adjusted HR (per 5 kg/m2
increase in BMI)

95% CI

26
1,012
2,823
1,972

1.44
1.17
1.04
1.10

1.00, 2.08
1.10, 1.26
1.00, 1.09
1.04, 1.15

N: number; HR: hazard ratio; BMI: body mass index; CI: confidence interval; APL: acute
promyelocytic leukemia; AML: acute myeloid leukemia; LL: lymphoid leukemias.

A

B

C

D

Figure 1. Relationship between body mass index (BMI) and log-hazard ratio (HR) for leukemias in the UK population. (A) Acute promyelocytic leukemia (APL); (B)
other acute myeloid leukemia (AML); (C) lymphoid leukemias; (D) all leukemias. Plots show mean (dark line) ± 95% confidence intervals (shaded area).
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APL (95%CI: 1.0-2.08), 1.17 for non APL-AML (95%CI:
1.10-1.26), 1.04 for LL (95%CI: 1.0-1.09), and 1.10 for
other leukemias (95%CI: 1.04-1.15) (Table 1 and Figure 1).
Stratification by gender suggested a stronger effect for
male gender in APL (HR 1.82, 95%CI: 1.10- 3.00 vs. female
HR 1.19, 95%CI: 0.67-1.98), although the sample size
becomes very small (n=13 each). Together, these results
suggest that higher BMI is associated with increased risk
of all sub-types of leukemia, particularly APL.

Cross-sectional studies in Italian, Spanish and US trial
cohorts
Though APL showed the strongest association with
higher BMI in the cohort analysis described above, results
were not conclusive due to the small number of cases
identified (n=26) and the consequently wide confidence
intervals. To strengthen the evidence, we carried out retrospective case-control studies using cohorts of APL

patients from national registries of clinical trials from
Spain (PETHEMA) and Italy (GIMEMA), and patients
from the US-based AML genome sequencing study (the
AML TCGA cohort with 22 additional cases characterized
at Washington University, St Louis, MO). In all three
groups, APL diagnosis was established using gold standard
diagnostic procedures.
Demographic characteristics of the three case cohorts
(Italy n=134, Spain n=414 and USA n=42) are described in
Table 2. Gender (female 53.0%, 55.2%, 50%, respectively)
and age (median of 45, 45, 47 years, respectively) were similarly represented. Information on ethnicity was unavailable
for the Spanish and Italian cohorts, whereas white, black
and hispanic ethnicities were represented in the US cohort.
To generate control groups for comparison, we obtained
anthropometric data from epidemiological surveys of the
general population in the different countries. As the prevalence of obesity has increased dramatically in most coun-

Table 2. Description of the cross-sectional cohorts.

Age

Gender
Year of diagnosis
Race

BMI

18 - 35
36 - 50
51 - 65
> 65
Median (IQR)
Male
Female
Median (range)
White
Black
Hispanic
Median (IQR)

Italy
n=134

Spain
n=414

USA
n=42

46 (34.3%)
34 (25.4%)
40 (29.9%)
14 (10.4%)
45 (31-57)
63 (47.0%)
71 (53.0%)
2002 (1997-2010)
26 (23-28)

113 (27.3%)
145 (35.0%)
102 (24.6%)
54 (13.0%)
45 (34-57)
227 (54.8%)
187 (45.2%)
2003 (1996-2012)
26 (23-29)

13 (31.0%)
12 (28.6%)
11 (26.2%)
6 (14.3%)
47 (33-60)
21 (50.0%)
21 (50.0%)
2007 (2001-2011)
36 (85.7)
5 (11.9)
1 (2.4)
34 (28-39)

IQR: interquartile range; BMI: body mass index; n: number.

Table 3. Observed body mass index (BMI) distribution in acute promyelocytic leukemia (APL) cases and expected BMI distribution in general
population (percentages in brackets).

Italy

Spain

USA

BMI

Obs

All
Expa

P

Obs

Males
Expc

P

Obs

Females
Expdc

<25.0
25.0-29.9
≥30.0
Total

48 (35.8%)
71 (53.0%)
15 (11.2%)
134

77.8 (58.0%)
44.8 (33.4%)
11.4 (8.5%)
134

<0.001

16 (25.4%)
42 (66.7%)
5 (7.9%)
63

29.0 (46.0%)
28.0 (44.5%)
6.0 (9.5%)
63

<0.001

32 (45.1%)
29 (40.8%)
10 (14.1%)
71

48.8 (68.7%)
16.8 (23.6%)
5.5 (7.7%)
71

<0.001

BMI

Obs

Expa

P

Obs

Expc

P

Obs

Expdc

P

<25.0
25.0-29.9
≥30.0
Total

172 (41.5%)
156 (37.7%)
86 (20.8%)
414

189.9 (45.9%)
158.1 (38.2%)
66.0 (15.9%)
414

0.011

79 (34.8%)
99 (43.6%)
49 (21.6%)
227

85.0 (37.4%)
103.2 (45.5%)
38.8 (17.1%)
227

0.130

93 (49.7%)
57 (30.5%)
37 (19.8%)
187

104.9 (56.1%)
55.9 (29.4%)
27.2 (14.6%)
187

0.033

BMI

Obs

Expb

P

Obs

Expc

P

Obs

Expdd

<25.0
25.0-29.9
30.0-34.9
≥35.0
Total

2 (4.8%)
13 (31.0%)
12 (28.6%)
15 (35.7%)
42

P

12.8 (30.6%)
13.7 (32.6%)
8.6 (20.5%)
6.9 (16.3%)
42

<0.001

1 (4.8%)
5 (23.8%)
9 (42.9%)
6 (28.6%)
21

5.3 (25.4%)
7.9 (37.7%)
4.8 (23.0%)
2.9 (13.9%)
21

0.002

1 (4.8%)
8 (38.1%)
3 (14.3%)
9 (42.9%)
21

7.5 (35.7%)
5.8 (27.6%)
3.8 (18.0%)
3.9 (18.8%)
21

0.003

P

Expected frequencies were obtained from the body mass index (BMI) distribution in the general population of the area of the acute promyelocytic leukemia (APL) cases, period
of APL diagnosis and in addition: aage class and gender; bage class, gender and race; cage class; dage class and race. Obs: observed.
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tries in the last decades (especially in the USA), we
obtained data that were as close as possible to the median
year of diagnosis (2002 for Italy, 2003 for Spain, 2007 for
the USA) (Table 3; see also Methods section).
In all three cohorts, there was strong evidence that the
observed BMI distribution for cases across World Health
Organization (WHO) BMI classes was different from that
expected under the null hypothesis of no association
(Italy: P<0.001; Spain: P=0.011; USA: P<0.001) (Table 3) in
gender-, age-, and ethnicity- (for USA) matched controls.
In particular, in all three datasets, there were more cases
than expected in the higher BMI groups, irrespective of
gender in all cohorts apart from Spain, in which significance was not reached for males (P=0.130) despite a similar trend (Table 3).

Correlation of TCGA transcriptomics data with body
mass index and acute myeloid leukemia subtype
The availability of the TCGA dataset prompted us to
search for signatures that could suggest a mechanistic
rationale for the association between APL and obesity. We
interrogated available AML transcriptomes with supervised gene set enrichment analysis using quSage.15
Focusing on the KEGG gene set collection, APL was associated with increased activity of 13 and decreased activity
of 64 out of 186 gene sets (Table 4, Figure 2A and Online
Supplementary Table S2). Intriguingly, among significantly
up-regulated gene sets, we found pathways associated
with the metabolism of long-chain unsaturated fatty acids
(linoleic and arachidonic), which are precursors of
eicosanoids mediating inflammation-associated cancers.18

A

B

Figure 2. Differential activities of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and insulin/leptin receptors in the M3 versus non-M3 quSage comparison in The Cancer Genome Atlas (TCGA). (A) Activity score with 95% Confidence Intervals (CI) of 186 KEGG gene sets; significant gene sets are color-coded in
red (if up-regulated) or green (if down-regulated). (B) Insulin/IGF1 receptor pathway and leptin receptors. Mean ± 95% confidence interval are plotted.

Table 4. Significantly up-regulated Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways in acute promyelocytic leukemia versus acute
myeloid leukemia in The Cancer Genome Atlas (TCGA).

pathway.name
KEGG_RENIN_ANGIOTENSIN_SYSTEM
KEGG_LINOLEIC_ACID_METABOLISM
KEGG_GLYCOSAMINOGLYCAN_BIOSYNTHESIS_HEPARAN_SULFATE
KEGG_GLYCOSPHINGOLIPID_BIOSYNTHESIS_LACTO_AND_NEOLACTO_SERIES
KEGG_ALANINE_ASPARTATE_AND_GLUTAMATE_METABOLISM
KEGG_ARACHIDONIC_ACID_METABOLISM
KEGG_GLYCOSAMINOGLYCAN_DEGRADATION
KEGG_HISTIDINE_METABOLISM
KEGG_ARGININE_AND_PROLINE_METABOLISM
KEGG_LIMONENE_AND_PINENE_DEGRADATION
KEGG_CARDIAC_MUSCLE_CONTRACTION
KEGG_PROTEIN_EXPORT
KEGG_PATHWAYS_IN_CANCER
haematologica | 2020; 105(6)

log.fold.change

P

FDR

0.6503
0.6381
0.4217
0.3391
0.3258
0.3221
0.3208
0.2996
0.2582
0.1662
0.1475
0.1439
0.1346

0.0023
0.0002
0.0000
0.0003
0.0009
0.0037
0.0000
0.0044
0.0001
0.0087
0.0084
0.0066
0.0169

0.0093
0.0010
0.0000
0.0017
0.0039
0.0130
0.0001
0.0148
0.0008
0.0250
0.0245
0.0204
0.0428
1563
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Also noticeable was the APL-associated upregulation of
insulin and insulin-like growth factor (IGF1) receptors, but
not leptin receptor (Figure 2B); insulin signaling-associated
pathways were also specifically up-regulated in obese versus non-obese APL patients ("type II diabetes mellitus" and
"insulin signaling") (Online Supplementary Table S2).
No pathway was significantly enriched in obese versus
non-obese patients among non-M3 cases.

Correlation of mutational data with body mass index
We then asked whether obesity is associated with specific driver mutations in AML in the TCGA cohort. Out of
23 established driver genes mutated at least twice in the
cohort, mutations in FLT3 were positively associated with
obesity (33 of 88 obese vs. 22 of 110 non-obese; OR=2.4,
FDR=0.16, P=0.007) (Figure 3 and Online Supplementary
Table S3). The correlation remained statistically significant
both in non-APL AML (27 of 49 obese vs. 22 of 102 nonobese; OR=2, P=0.04,) and in APL (6 of 12 obese vs. 0 of 8
non-obese; P=0.04). When we analyzed the two main
classes of FLT3 mutations separately [tyrosine kinase
domain (TKD) and internal tandem duplication (ITD)], the
association held statistically significant for ITD (24 of 88
obese vs. 14 of 110 non-obese; OR=2.6, P=0.01) but not
for TKD (9 of 88 obese vs. 8 of 110 non-obese; P=0.6). In
APL, where all FLT3 mutations were ITD, the correlation
remained statistically significant (6 of 12 obese vs. 0 of 8
non-obese; P=0.04). In non-APL AML, with 32 ITD and 17
TKD, overall FLT3 mutations were still significantly
enriched in obese patients ((27 of 49 obese vs. 22 of 102
non-obese; OR=2, P=0.04) but not when analyzed separately (P=0.11 for ITD and 0.44 for TKD).
We then attempted to validate this finding in the APL
cohorts, for which data on the most representative
FLT3ITD mutation (ITD) were available (Table 5). In the
pooled analysis (163 mutated patients, of a total 569), OR
of having a FLT3 ITD was 1.22 (95%CI: 1.05-1.43) per each
5 kg/m2 increase. In the individual cohorts, results were significant in the Italian (30 of 114 mutated, OR=2.35,
95%CI: 1.25-4.42) and US (14 of 41 mutated, OR=1.44,
95%CI: 0.93-2.24) cohorts, but not in the Spanish (119 of
414 mutated, OR=1.09, 95%CI: 0.89-1.33).

obesity prevalence and dietary habits. In addition, we provide hypothesis-generating evidence for molecular mechanisms underlying such an association, in particular, the
possible involvement of pro-inflammatory fatty acid
metabolism and mutations of the tyrosin kinase FLT3.
Our epidemiological results expand a growing body of
literature identifying overweight/obesity as a bona fide risk
factor for leukemias. The most recent meta-analysis
reported an adjusted relative risk of 1.14 (95%CI: 1.041.26; P=0.008) for AML overall.5 Despite the growing evidence, the notion of obesity as a risk factor for leukemia
remains widely overlooked.7 Among the highly heterogeneous AML subtypes, APL is the most clinically and biologically coherent. We and others previously showed that
in APL, but not in other AML, an elevated BMI significantly affects outcome.10,19 This is also in line with the few retrospective studies that have assessed APL as a separate
disease entity.20,21 No study had addressed this question
prospectively, a task made difficult by the rarity of the disease, but made possible in our case by the very large study

Discussion
Here we provide substantial evidence for an association
between elevated BMI and risk of developing AML. The
risk was particularly high with the APL subtype, with an
estimated 44% HR increase per each 5 kg/m2. This was
qualitatively confirmed by comparing expected versus
observed BMI distributions in APL cohorts across three
western countries (the USA, Spain and Italy) with different

Figure 3. Association between obesity and FLT3 mutations. (A) Bubble plot representing Odds Ratio versus -logP value (mLogPval) of any mutation in 23 driver
genes in The Cancer Genome Atlas (TCGA) acute myeloid leukemia cohort. FLT3
(in red) is the only gene with False Discovery Rate (FDR) < 0.25. Bubble size
reflects the number of obese patients with a mutation. Data are tabulated in
Online Supplementary Table S3.

Table 5. Logistic regression of body mass index (BMI) and FLT3 ITD mutations.

BMI
5 unit increase
≥ 25 vs. <25b
≥ 30 vs. <30b

All 3 cohorts 163/569a
OR (95% CI)

ITALY 30/114a
OR (95% CI)

SPAIN 119/414a
OR (95% CI)

USA 14/41a
OR (95% CI)

1.22 (1.05-1.43)
-

2.35 (1.25-4.42)
4.40 (1.63-11.9)
-

1.09 (0.89-1.33)
1.15 (0.75-1.78)
-

1.44 (0.93-2.24)
6.46 (1.21-34.5)

Mutations / All patients. bGiven the small number of obese patients in Italy and Spain, we compared overweight/obese patients versus normal weight patients (i.e. BMI ≥ 25 vs.
<25). Given the small number of normal weight patients in the USA, we compared obese patients versus non-obese patients (i.e. BMI ≥ 30 vs. <30). OR: odds ratios; CI: confidence
intervals.
a
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population (5.2 million). The largest prospective study to
date (EPIC), which revealed a statistically significant higher risk only in female AML, but not in other gender and
biological subgroups,4 was based on a relatively small
number of incident cases: only 671 out of 375,021 participants over 11.5 years of median follow up. The use of
orthogonal epidemiological approaches is a strength of the
study, as it attempts to mitigate some weaknesses of each
design. Registry-based studies have little patient selection
bias, providing results that are more comparable to reallife scenarios. However, the quality of case identification
is likely to be sub-optimal; erroneous assignment of APL
to the general AML ICD code might "deplete" incident
cases and further reduce statistical power. Case-control
studies in the context of clinical trials, on the other hand,
offer the advantage of gold standard diagnosis but might
be affected by significant patient selection biases. This
may have counter-selected obese patients in the present
study, since the correlated comorbidities may be associated with limited access to clinical trials.
Another limitation of the study is that we could not provide the same degree of geographical homogeneity for
control subjects in the case-control studies. This may be
particularly relevant for the USA, known to have wide
state-specific differences in BMI distribution. However,
this variation is mainly due to demographic parameters,22
such as age, gender and race, and is, therefore, at least
partly accounted for in our multivariate analysis. We also
note that our US APL cohort includes a single patient of
hispanic ethnicity. Hispanics are considered at higher incidence of APL, although some large studies based on
Surveillance, Epidemiology, and End Results (SEER) data
dispute this commonly held conclusion.23
Understanding the molecular mechanism causing
increased cancer risk in obese subjects is crucial for adequate nutritional management in disease prevention, given
the sustained rise of obesity worldwide, particularly in
emerging economies. The possibility of matching transcriptional and mutational profiles from TCGA to patient
clinical and BMI data provided an opportunity to generate
hypotheses grounded on actual data. However, extracting
biological significance from large molecular datasets
remains challenging. Shifting the analytical focus from single genes to gene sets or pathways may allow signals to be
captured even when the changes affecting individual genes
are minimal, provided they are coherent. The gene setbased method we used here for transcriptional analysis
does not assume equal variances, resulting in improved
sensitivity and specificity over similar competing
methods.15 Our main finding is the upregulation of several
genes involved in the metabolism of pro-inflammatory ω6 polyunsaturated fatty acids (PUFA, linoleic and arachidonic) in APL. These molecules are increased in the plasma
of metabolically impaired subjects, including the obese,24
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